This search looks for keywords in all of the website’s content. Search tips
Filter by
- Agenda(0)
- Annex to CHMP highlights(0)
- Annual Report(0)
- Application withdrawal assessment report(0)
- Committee meeting report(0)
- COVID-19 vaccine safety update(0)
- Direct healthcare professional communication(0)
- EPAR - All authorised presentations(0)
- EPAR - Amended Product Information(0)
- EPAR - Assessment report - Variation(0)
- EPAR - Assessment report on maintenance of orphan designation - Initial authorisation(0)
- EPAR - Assessment report on maintenance of orphan designation - Post-authorisation(0)
- EPAR - Conditions imposed on member states for safe and effective use(0)
- EPAR - Full risk management plan(0)
- EPAR - Overview(0)
- EPAR - Paediatric investigation plan compliance statement(0)
- EPAR - Procedural steps taken and scientific information after authorisation(0)
- EPAR - Procedural steps taken before authorisation(0)
- EPAR - Product Information(0)
- EPAR - Public assessment report(0)
- EPAR - Risk-management-plan summary(0)
- EPAR - Scientific conclusion(0)
- EPAR - Scientific Discussion(0)
- EPAR - Scientific Discussion - Variation(0)
- EPAR - Steps taken after authorisation when a cutoff date has been used(0)
- Herbal - Call for data(0)
- Herbal - Herbal monograph(0)
- Herbal - HMPC assessment report(0)
- Herbal - HMPC opinion on a European Union herbal monograph(0)
- Herbal - List of references supporting the assessment report(0)
- Herbal - Overview of comments received during consultation(0)
- Herbal - Summary of assessment report for the public(0)
- Herbal – European Union herbal monograph(0)
- Herbal – European Union list entry(0)
- Leaflet(0)
- Maximum Residue Limits - Divergent opinion(0)
- Maximum Residue Limits - Opinion(0)
- Maximum Residue Limits - Report(0)
- Maximum Residue Limits - Summary of opinion(0)
- Medicine QA(0)
- Medicines under additional monitoring(0)
- Minutes(0)
- Newsletter(0)
- Opinion on any scientific matter(0)
- Opinion outside EU - All presentations(0)
- Opinion outside EU - Assessment report - Variation(0)
- Opinion outside EU - Medicine questions and answers(0)
- Opinion outside EU - Procedural steps taken and scientific information after opinion(0)
- Opinion outside EU - Procedural steps taken before opinion(0)
- Opinion outside EU - Product information(0)
- Opinion outside EU - Public assessment report(0)
- Opinion outside EU - Risk-management-plan summary(0)
- Opinion outside EU - Scientific discussion(0)
- Opinion outside EU - Summary for the public(0)
- Opinion outside EU - Summary of opinion(0)
- Opinion outside EU - Summary of opinion - Initial authorisation(0)
- Opinion outside EU - Withdrawal assessment report(0)
- Orphan designation(0)
- Orphan review(0)
- Other(0)
- Overview of comments(0)
- Parallel distribution(0)
- Periodic safety update single assessment(0)
- PIP - Notification of discontinuation of a paediatric development which is covered by an agreed PIP decision(0)
- PIP - Paediatric-investigation-plan summary(0)
- PIP decision(0)
- Position statement(0)
- PRAC recommendation on signal(0)
- Presentation(0)
- Press Release(0)
- Procurement(0)
- Public Statement(0)
- Recommendation on medication errors(0)
- Recruitment(0)
- Referrals document(0)
- Regulatory and procedural guideline(0)
- Report(0)
- Scientific guideline(0)
- Standard Operating Procedure - SOP(0)
- Summary of opinion(0)
- Summary of opinion - Initial authorisation(0)
- Supply shortage(0)
- Template or form(0)
- Withdrawal letter(0)
- Work Instruction - WIN(0)
- Work programme(0)
- Advanced therapies(398)
- Antimicrobial resistance(46)
- Biologicals(24)
- Biosimilars(151)
- Brexit(30)
- Careers(3)
- Clinical trials(185)
- Compassionate use(4)
- Compliance and inspections(105)
- Corporate(51)
- COVID-19(466)
- Data on medicines(169)
- Early access(25)
- Fees(13)
- Generic and hybrid medicines(400)
- Governance(91)
- Innovation(281)
- Maximum residue limit(17)
- Medication error(6)
- Medicines(7829)
- Medicines for use outside the EU(29)
- Medicine shortages(126)
- Mpox(17)
- Paediatrics(3123)
- Parallel distribution(6)
- Pharmacovigilance(2935)
- Procurement(10)
- Product information(61)
- Quality of medicines(85)
- Rare diseases(3275)
- Referrals(381)
- Regulatory and procedural guidance(552)
- Research and development(228)
- Scientific advice(38)
- Scientific guidelines(1014)
- SME(63)
- Vaccines(382)
- Veterinary limited markets(15)
Search results (24232)
tirzepatide
Diabetes Mellitus, Type 2
Obesity
Overweight
Date of authorisation:
Revision:
8
Last updated:
MedicineHumanAuthorised
The European Medicines Agency (EMA) charges fees for the services it provides. The rules relating to the Agency's fees are governed by the fee regulation (Council Regulation (EC) No 297/95) and its implementing rules, as well as the pharmacovigilance fee regulation (Regulation (EU) No 658/2014).
Last updated:
HumanVeterinaryCorporateFeesRegulatory and procedural guidanceMedicines
zoledronic acid
Cancer
Fractures, Bone
Date of authorisation:
Revision:
38
Last updated:
MedicineHumanAuthorised
entecavir
Hepatitis B, Chronic
Date of authorisation:
Revision:
28
Last updated:
MedicineHumanAuthorised
azithromycin
Article 31 referrals
Status:
Under evaluation
Last updated:
ReferralHuman
inclisiran
Hypercholesterolemia
Dyslipidemias
Date of authorisation:
Revision:
7
Last updated:
MedicineHumanAuthorised
atezolizumab
Carcinoma, Transitional Cell
Carcinoma, Non-Small-Cell Lung
Urologic Neoplasms
Breast Neoplasms
Small Cell Lung Carcinoma
Date of authorisation:
Revision:
27
Last updated:
MedicineHumanAuthorised
deucravacitinib
Psoriasis
Date of authorisation:
Revision:
4
Last updated:
MedicineHumanAuthorised
turoctocog alfa pegol
Hemophilia A
Date of authorisation:
Revision:
7
Last updated:
MedicineHumanAuthorised
pegfilgrastim
Neutropenia
Date of authorisation:
Revision:
5
Last updated:
MedicineHumanAuthorised